First-ever clinical trial exclusively conducted among people with hard-to-treat form of tuberculosis known as pre-extensively drug-resistant TB shows many patients benefit from shorter, simpler regimens. Not all patients benefited from the shorter, gentler course of treatment, prompting researchers to urge caution and carefully evaluate disease severity prior to selecting treatment. 

In those with more severe tuberculosis, the new treatment did not always resolve the disease, a finding that highlights the importance of tailored treatment strategies.